BioFIT and the WBC Incubator are pleased to announce that they will be putting together a special edition of WBC Club during BioFIT 2018 in Lille. This session, called «Would-be CEO Networking Lunch», will be held on the second day of BioFIT (5th December).

As talented CEOs are so much sought-after by so many stakeholders of the biotech industry, to both launch and drive new companies to success, this special WBC Club session will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this crucial issue.

Since 2010, WBC Incubator has validated close to 100 biotech professionals in Belgium for their ability to match and work with scientific founders and entrepreneurs with the collective aim to build together more exciting business plans, stronger investment propositions and faster business development programmes. In Belgium, biotech CEOs and Would-be CEOs meet regularly to discuss business opportunities during so-called WBC Club events.

The «Would-be CEO Networking Lunch» is organised to present the WBC incubation model to BioFIT participants. Please also note that Would-be CEOs will be identified using the BioFIT partnering platform.

Any bioentrepreneur looking for a project to get involved in is welcome to join BioFIT and particularly this would-be CEOs networking lunch. Any incubator or tech transfer entity looking for an entrepreneur to lead their start-up launch projects is also welcome to join.

In 5 days, it will be too late to enjoy the Early Bird offer!

If you are interested in attending BioFIT on 4th and 5th December 2018 in Lille, France,  enjoy the Early Bird offer before it ends, after this Saturday it will be too late!

Book your booth now!

As an Exhibitor, you will gain high visibility among top leaders in the Life Sciences sector.
Ideally located at the focal point of the event, the Exhibition area enables participants to access key information, expand their network, highlight their skills, services and innovations and enhance their visibility.

6m² fitted booth – € 2,200
(1 partnering pass included)

9m² fitted booth – € 3,300
(1 partnering pass included)

12m² fitted booth – €4,400
(1 partnering pass included)

18m² fitted booth – €6,600
(2 partnering passes included)

 

BioFIT 2018 will host the 4th edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal healthcare industry (SIMV)’s initiative, on the 4th and 5th of December 2018, in Lille.

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

About SIMV

While being the organiser of this meeting, the SIMV intends to federate research actors by actively contributing to meet the needs in animal health innovation. In particular, enhanced research is needed to supplement and renew the therapeutic arsenal for the treatment of infectious diseases and therefore research and innovation on this topic should be promoted.

Many thanks to LFB for joining BioFIT 2018 as a Contributing Sponsor!

Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare. The LFB Group is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are medicinal products derived from living organisms in three major fields of therapy: immunology, haemostasis and intensive care.

The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.

LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in nearly 60 countries. Over 2000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients. Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.

Join key BioFIT 2018 sponsors such as Bayer, Roche, MSD, Boehringer Ingelheim, Pfizer and VIB, to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

#BioFIT2018 preliminary programme is now available

In this brochure, you will find all the information you need about the 7th edition of the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation in the field of Life Sciences. 

Many thanks to Pfizer for joining BioFIT 2018 as a Bronze Sponsor!

Pfizer is a leading research-based biopharmaceutical company. They apply science and their global resources to deliver innovative therapies that extend and significantly improve lives. They make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands.

Pfizer teams work in developed and emerging markets to treat, cure and eradicate life-threatening conditions and challenge some of the most feared diseases of our time. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Join key BioFIT 2018 sponsors such as Bayer, RocheMSDBoehringer Ingelheim and LFB, to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

 

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

Are you a tech transfer with a ready-to-be-licensed technology? 

Apply to the presentation sessions to:

  • Promote your innovations
  • Receive a speed-monitoring from pharma, biotech, TTO and investors
  • Find partners who could support your project
applyyy

1. Apply
Dedicated to TTO, universities or related structures that have ready-to-be-licensed technologies

be selected

2. Be selected
A jury of experts will select the most innovative projects

picto19 (2)

3. Exhibit
The selected candidates will benefit from a poster’s exhibition at bioFIT describing their out-licensing opportunities

pitch

4. Pitch
Presentations of the selected projects to potential industrial partners during BioFIT

speed mentoring

5. Find partners
The presenters can easily find industrial partners who could in-license their assets

Conference Insight – Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?

4 Dec 2018 9:30 – 11:00 am

The seed investment market is composed of actors with really diverse degree of specialisation (from totally agnostic and multi-sectorial to pure players in specific therapeutic indications). Do the most specialised funds attract more generalist ones in the financing rounds? What is the respective importance today in the amount of seed investment of the multi-sectorial funds, the 100% healthcare orientated funds and the pure players in the biotech sector.

They will share their experience:

  • Jan Adams, Managing Director, EMBL Ventures (DE)
  • Jonathan Tobin, Investment Director, Arix Bioscience (UK)

Discover the new speakers that will share their vision at BioFIT 2018:

Over 70 international experts from academia, industry and biotech will address issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge.

The last confirmed speakers are:


Alain Chevallier
Life Sciences Partner
Truffle Capital


Marco A. Chacon

Assistant Vice President of Industry Alliances
University of Maryland Baltimore


Rodolphe Besserve

Head SuFT Advisory, Start-up & French Techs
Société Générale Corporate Investments and Banking


Zishan Haroon
Chairman and General Partner
JulzCo